SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending due to discussions around a potential short squeeze and recent volatility, sparked by news of their expansion into menopause treatments. The stock's price action is seeing a lot of back and forth between bulls and bears. Some traders point to the potential for further gains, while others cite concerns about valuation and management actions.

Aventus Network

Aventus Network ($AVT) is trending, with community members expressing excitement about its potential, particularly its Aventus Cloud service. Discussion includes its interoperability with Polkadot and Ethereum, as well as its listing on Coinbase. Some users believe $AVT is undervalued and poised for significant growth.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to levels not seen in over a decade, driven by a potential short squeeze and global demand for bullion. Community discussions revolve around whether the rally is sustainable, with some citing supply shortages and a potential for further gains, while others warn of a possible pullback. The broader context includes concerns about the dollar and traditional safe haven assets.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as investors discuss its potential in the evolving app store landscape, particularly following recent rulings impacting Google's Play Store policies. Community members are speculating on how the company might capitalize on these changes and forge new partnerships, with some drawing comparisons to the AI-driven growth of companies like Applovin. Bullish sentiment is building amidst discussions of potential short squeezes and a multi-year uptrend.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending following news of FDA fast track designation, sparking significant community discussion and a surge in price and volume. Traders are pointing to technical indicators and potential short squeezes, while analysts have increased price targets. The community is actively debating potential breakout levels and the stock's overall potential in the biotherapeutics space.

Aptera Motors Corp. is an automotive technology company focused on the development, production, and distribution of energy-efficient, solar-powered, battery-electric vehicles. Its flagship product, the Aptera, is a three-wheeled, two-seat solar vehicle designed to reduce reliance on traditional charging by utilizing integrated solar panels. The company was founded by Steve Fambro and Chris Anthony and is headquartered in San Diego, CA.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending due to high volatility following its direct listing, with community members actively discussing trading halts and potential market manipulation.  While some investors express excitement about the company's solar EV technology and pre-order demand, others voice concerns about production timelines and the vehicle's design.  The stock's extreme price fluctuations have fueled speculation about short squeezes and long-term potential within the EV sector.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is surging, fueled by safe-haven demand amid economic uncertainty and global dissatisfaction. The community is debating whether this rally signals a blow-off top or a continuation of the upward trend, with some expressing concerns about overbought conditions and potential pullbacks. Discussions also revolve around the interplay between gold, the dollar, and potential shifts in global economic power.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending due to investor reactions to its AI strategy and cloud infrastructure spending, particularly after the company's AI World event. While some analysts are optimistic about long-term revenue potential, the community is concerned about near-term profitability, rising debt, and heavy capital expenditure, leading to a sell-off despite positive AI cloud deals.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab ($GTLB) is trending amid takeover speculation, with Datadog ($DDOG) and Google ($GOOGL) mentioned as potential acquirers and a possible bidding war. The community is weighing the potential deal price, with some focusing on a $50 breakout level while others suggest a price above $60 per share is more realistic. Despite the takeover buzz, some traders dismiss the rumors and express concern about the stock's performance.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

CVM is trending as investors await a potential decision from the Saudi Food and Drug Authority (SFDA) regarding Cel-Sci's application for Breakthrough Medicine Designation for Multikine. Community members are debating the timeline for the SFDA's decision and its potential impact, with some expressing skepticism towards the CEO's statements, while others highlight the partnership with Dallah Pharma and potential for commercialization in Saudi Arabia.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fossil Group (FOSL) shares were down nearly 39% in premarket trading on Thursday morning after the company said on Thursday that it has further extended the&nbsp;expiration of the exchange offer concerning its 7.00% Senior Notes due 2026.The company also noted that it has extended the consent solicitation and its concurrent rights offering from October 15 to October 22.Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.Retail sentiment on Fossil Group jumped to ‘extremely bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Wednesday, Fossil Group’s shares had closed up 41.5% at a two-and-a-half-year high of $3.75 following the news of the IPO of its Indian unit. According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/fossil-india-is-said-to-weigh-ipo-that-could-raise-400-million">Bloomberg News report</a>, Fossil India was in talks to raise $300 million to $400 million by selling as much as a 25% stake.The report noted that the talks were ongoing and that the size of the IPO or the possible timing of the offering could change.&nbsp;In early 2025, as part of a plan to save costs, the company planned to shut down around 50 retail locations and shift certain international markets to a distributor model. The firm is home to several premium brands such as Fossil Watches and Michele.&nbsp;<a href="https://stocktwits.com/symbol/VERI">Shares of Fossil Group</a> have jumped 125% this year and gained nearly 213% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>

Sign of Fossil Group outside a store in Orlando, Florida.

FOSL Stock Plunges After Extending Exchange Offer For Its Senior Notes Due 2026

Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.

Equity

Shares of Ovid Therapeutics Inc. (OVID) jumped 18% in the pre-market session on Friday after the company announced positive results from an early-stage trial of its OV329, as well as the pricing of a $175 million placement.OV329 is being developed for the potential treatment of rare and treatment-resistant forms of epilepsy and seizures. It is believed to work by reducing the activity of GABA-AT, an enzyme that degrades GABA, an important inhibitory neurotransmitter in the brain. An increase in levels of GABA in the brain can potentially suppress neuronal hyperexcitability, known to cause seizures, the company said.The early-stage <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-announces-positive-topline-results-for-the-next-generation-GABA-aminotransferase-inhibitor-OV329-that-demonstrate-strong-inhibitory-activity-and-a-potential-best-in-category-safety-profile/default.aspx">study</a>, which enrolled 68 healthy volunteers, was aimed at evaluating the safety, tolerability, pharmacokinetic, and pharmacodynamic activity of OV329. The drug demonstrated statistically significant inhibition of GABA-AT, matching or exceeding the inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor Vigabatrin (VGB), the company said. The drug also demonstrated a favorable safety and tolerability profile, it added. &nbsp;The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. The study is expected to start in Q2 2026 and be completed in mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OVID">OVID stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_8_04_20_AM_png_cfbcdadc7f.webp" alt="OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>Separately, Ovid on Friday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-Therapeutics-Announces-Pricing-of-Private-Placement-Totaling-up-to-175-Million-in-Gross-Proceeds/default.aspx">announced</a> the pricing of a private placement totaling up to $175 million in proceeds. The financing transaction included participation from new investors alongside existing ones, the company said.The company stated that it intends to utilize the net proceeds from the initial closing of the financing deal, in conjunction with its existing cash, cash equivalents, and marketable securities, to fund research and development, general corporate expenses, and working capital requirements. It added that it expects its cash to fund its operating plan into 2028.A Stocktwits user applauded the funding news as “huge.”<stembedurl>https://stocktwits.com/Skeetz99/message/630905995</stembedurl>OVID stock is up 76% this year and approximately 45% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.

Eastman Kodak Co. (KODK) experienced a 366% surge in Stocktwits retail chatter in the last 24 hours after the photographic film products maker announced on the X platform that it is making a major move to strengthen pharmaceutical manufacturing within the U.S.&nbsp;&nbsp;<figure class="image"><img style="aspect-ratio:587/183;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_082242_png_3c927c29c7.webp" alt="Screenshot 2025-07-24 082242.png" width="587" height="183"></figure>A Stocktwits user said it is the ‘Kodak Moment’ for the company.<stembedurl>https://stocktwits.com/ScottBrownMBA/message/622209783</stembedurl>Another user expressed optimism, linking the news to the U.S. Japan trade deal.<stembedurl>https://stocktwits.com/Zorrelak/message/622217804</stembedurl>However, retail sentiment around the stock remained in ‘bearish’ territory with ‘low’ message volume levels.<figure class="image"><img style="aspect-ratio:975/117;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_083017_png_ac1c90c79d.webp" alt="KODK’s Sentiment Meter and Message Volume as of 08.30 a.m. ET on July 24, 2025 | Source: Stocktwits" width="975" height="117"><figcaption>KODK’s Sentiment Meter and Message Volume as of 08.30 a.m. ET on July 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/KODK">Eastman Kodak stock</a> inched 0.5% higher in Thursday’s premarket.Kodak ventured into pharmaceuticals after the company was awarded a $765 million federal loan in 2020, aimed at producing pharmaceutical ingredients, as part of a broader effort during the pandemic to strengthen the nation’s medical supply chain.In May of this year, CEO Jim Continenza stated that the company is retrofitting a facility at Eastman Business Park and has committed $20 million to expand U.S. manufacturing, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://rbj.net/2025/05/09/kodak-invests-20m-in-rochester-pharma-manufacturing-expansion/?utm_source=chatgpt.com">report</a> from the&nbsp;Rochester Business Journal.&nbsp;In the first quarter (Q1), the company’s revenue declined 1% year-on-year (YoY) to $243 million.&nbsp;“The group’s new cGMP manufacturing facility, which we expect to be online later this year, will expand our current pharma business into manufacturing FDA-regulated diagnostic test reagents. Our investment in the new pharma facility is just one example of our commitment to investing in U.S.-based manufacturing,” said&nbsp;Continenza after the Q1 earnings.As it evolves into pharmaceuticals, Kodak continues to support its traditional film operations and printing systems, including high-speed inkjet technology.Eastman Kodak stock has gained over 8% year-to-date and over 25% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-manhattan-associates-at-and-t-draw-heavy-retail-chatter-on-stocktwits/ch8yupaR5HI">Alphabet, Manhattan Associates, AT&amp;T Draw Heavy Retail Chatter On Stocktwits Among Tech Stocks: More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

A Kodak ‘Moment’? Company’s Pharma Expansion Plans Ignite 366% Surge In Retail Chatter

Kodak ventured into pharmaceuticals after the company was awarded a $765 million federal loan in 2020, aimed at producing pharmaceutical ingredients, as part of a broader effort during the pandemic to strengthen the nation’s medical supply chain.

Diversified Energy (DEC) stock gained in pre-market trade on Monday after the company said it would buy Maverick Natural Resources from private equity firm EIG for $1.28 billion.The deal, expected to close in the first half of 2025, would increase the share of oil in Diversified Energy’s total energy production mix.The energy firm said the deal would help nearly double its revenue, and the combined company would have a total production of about 200,000 barrels of oil equivalent per day.The overwhelming majority of Maverick’s production comes from the Western Anadarko Basin, the Ark-La-Tex region of East Texas, and the largest U.S. shale oilfield Permian Basin.Over the past one and half years, the Permian has been a focal point of deal activity in the U.S. due to its robust infrastructure and relatively lower production costs.<a href="https://stocktwits.com/symbol/DEC">Diversified Energy</a> said EIG would own 20% of the combined company once the transaction closes.Rusty Hutson, the CEO of Diversified Energy, will continue to serve in his position after the deal is completed.“The acquired producing assets have demonstrated leading well performance and are a natural fit with our operating advantage and existing acreage,” Hutson said.The company said it is liable to pay $50 million in termination fees under certain circumstances.Retail sentiment on Stocktwits jumped to ‘extremely bullish’ (96/100) territory from ‘bearish’(36/100) a day ago, while retail chatter remained ‘extremely high’.<figure class="image"><img style="aspect-ratio:886/206;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DEC_Jan_27_e4c793b801.JPG" alt="DEC’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on Jan. 27, 2025 | Source: Stocktwits" width="886" height="206"><figcaption>DEC’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on Jan. 27, 2025 | Source: Stocktwits</figcaption></figure>Earlier this month, Diversified Energy had agreed to buy some natural gas assets from Summit Natural Resources for $45 million.Over the past year, the stock has gained 32.5%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/super-micro-stock-crashes-below-30-support-premarket/chbkvyQRov">Super Micro Stock Crashes Below $30 Support Premarket As DeepSeek Fears Rattle AI Stocks: Retail Sentiment Mixed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An oil pumpjack in a field on March 24, 2024 in Grandfalls, Texas. (Photo by Brandon Bell/Getty Images)

Diversified Energy Stock Rises After Deal To Buy Maverick Natural Resources for $1.28B: Retail’s Elated

The deal, expected to close in the first half of 2025, would increase the share of oil in Diversified Energy’s total energy production mix.

EA Series Trust - EA Bridgeway Omni Small-Cap Value ETF

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

BSVO
EA Series Trust - EA Bridgeway Omni Small-Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BSVO News

BSVOEA Series Trust - EA Bridgeway Omni Small-Cap Value ETF